TLDR: UNH, MOH, NVO, LLY, ELV, TMO, DHR, ABT. Help me pick 1-4.
Longer version:
I initially bought Pfizer without knowing anything about stocks. It makes up about 5% of my portfolio now and really just seemed like a default buy. I now realize my mistake. My plan is to average down and then sell it once I reach a break even price (it's pretty cheap right now imo – PE is only 7, and even if I fuck this up, I'm confident it'll reach my buy price eventually…or maybe I'm shooting myself in the foot, who knows). Anyway, point is that I'm not interested in Pfizer anymore and I don't have any other healthcare stocks.
My portfolio is growth-focused. Dividends are nice, sure, but not something I'm actively looking for. medium risk tolerance, but I'm only interested in stocks with a minimum mkt cap of $10b and nothing with a PE over 50 (yes, LLY is pushing it). If there is a stock not listed above that you think fits these requirements, please let me know! But for now, these are the ones I've come up with.
UNH seems to be the favourite and the largest. It's down a bit right now, and I like it. Health insurance could face some headwinds because politics, but should be fine in the long term, I think (after Obama's presidency, I'm convinced that the US just hates affordable healthcare). However, it's grown to be quite the monster already, which is why I also have MOH in there. TMO and DHR just seem great, and I have a preference for TMO but it seems a bit expensive right now (high PE historically). Might end up buying both just to be safe? Instruments won't be as affected as, say, pharma companies. I have NVO and LLY in there for pharma, but I'm concerned about drug patent expirations etc. and the necessity to continuously invent new drugs. Little hesitant with these. LLY seems ridiculously expensive right now to boot, and I'm not sure o what extent NVO will be affected by new diabetes-related price changes. Threw ABT in because I hear about it so much. Haven't looked into that one a lot but doesn't seem to specialize as much as some of these other ones.
Still researching, still learning. If anyone has any insights, analyses, suggestions, or directions to send me in, I'd gladly welcome them to voice their opinions.
Leave a Reply